Small extracellular vesicle-mediated targeting of hypothalamic AMPKα1 corrects obesity through BAT activation.
- Milbank, E.
- Dragano, N.R.V.
- Gonzales García, I.
- Garcia, M.R.
- Rivas-Limeres, V.
- Perdomo, L.
- Hilairet, G.
- Ruiz-Pino, F.
- Mallegol, P.
- Morgan, D.A.
- Iglesias-Rey, R.
- Contreras, C.
- Vergori, L.
- Cuñarro, J.
- Porteiro, B.
- Gavaldà-Navarro, A.
- Oelkrug, R.
- Vidal, A.
- Roa, J.
- Sobrino, T.
- Villarroya, F.
- Diéguez, C.
- Nogueiras, R.
- García-Cáceres, C.
- Tena-Sempere, M.
- Mittag, J.
- Carmen Martínez, M.
- Rahmouni, K.
- Andriantsitohaina, R.
- López, M.
DOIAbstract
Current pharmacological therapies for treating obesity are of limited efficacy. Genetic ablation or loss of function of AMP-activated protein kinase alpha 1 (AMPKα1) in steroidogenic factor 1 (SF1) neurons of the ventromedial nucleus of the hypothalamus (VMH) induces feeding-independent resistance to obesity due to sympathetic activation of brown adipose tissue (BAT) thermogenesis. Here, we show that body weight of obese mice can be reduced by intravenous injection of small extracellular vesicles (sEVs) delivering a plasmid encoding an AMPKα1 dominant negative mutant (AMPKα1-DN) targeted to VMH-SF1 neurons. The beneficial effect of SF1-AMPKα1-DN-loaded sEVs is feeding-independent and involves sympathetic nerve activation and increased UCP1-...
Add to ORKG